Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies

This article reviews the current evidence for clinical effectiveness, as well as safety of SCIg for the treatment of immune-mediated neuropathies, and addresses remaining open questions in this context.
We conclude that despite the need for controlled long-term studies to demonstrate long-term efficacy of SCIg in immune-mediated neuropathies, SCIg may already represent a potential therapeutic alternative for selected patients.

Source: Therapeutic Advances in Neurological Disorders - June 20, 2016 Category: Neurology Authors: Leussink, V. I., Hartung, H.-P., Kieseier, B. C., Stettner, M. Tags: Reviews Source Type: research